Scarica l'app Stockscreener
92.25
2.23%
-2.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$94.35
Aprire:
$95.6
Volume 24 ore:
773.38K
Relative Volume:
0.95
Capitalizzazione di mercato:
$5.78B
Reddito:
$434.41M
Utile/perdita netta:
$-128.05M
Rapporto P/E:
-43.72
EPS:
-2.11
Flusso di cassa netto:
$-250.52M
1 W Prestazione:
-1.80%
1M Prestazione:
-17.60%
6M Prestazione:
-2.67%
1 anno Prestazione:
+5.72%
Intervallo 1D:
$91.71
$95.60
Intervallo di 1 settimana:
$90.84
$96.78
Portata 52W:
$80.42
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
92.25 | 5.78B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | JP Morgan | Overweight |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Reiterato | Needham | Buy |
| 2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Iniziato | Berenberg | Buy |
| 2022-07-08 | Iniziato | Oppenheimer | Outperform |
| 2022-06-27 | Iniziato | Wells Fargo | Underweight |
| 2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-01 | Iniziato | Citigroup | Neutral |
| 2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Ripresa | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-11-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-02 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Equal Weight |
| 2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Iniziato | Piper Jaffray | Neutral |
| 2019-08-15 | Ripresa | Raymond James | Mkt Perform |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-05-23 | Ripresa | Goldman | Buy |
| 2019-04-03 | Iniziato | Morgan Stanley | Overweight |
| 2018-09-25 | Iniziato | Leerink Partners | Outperform |
| 2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
989 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Asset Management One Co. Ltd. - Defense World
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - Defense World
Stifel maintains Blueprint Medicines stock Buy rating, $155 target - Investing.com
Blueprint Medicines' SWOT analysis: strong ayvakit sales fuel growth as stock eyes $140 - Investing.com
What is Leerink Partnrs’ Forecast for BPMC Q1 Earnings? - Defense World
Blueprint Medicines (NASDAQ:BPMC) Lowered to Sell Rating by StockNews.com - Armenian Reporter
Stephens Inc. AR Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at Needham & Company LLC - Defense World
HC Wainwright Reaffirms “Buy” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Blueprint Medicines (NASDAQ:BPMC) Rating Lowered to “Sell” at StockNews.com - Defense World
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Wedbush Reiterates Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline - Nasdaq
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines price target raised to $135 from $127 at Baird - TipRanks
Blueprint Medicines Corporation (NASDAQ:BPMC) Is Expected To Breakeven In The Near Future - Simply Wall St
Strong Buy Rating for Blueprint Medicines: Ayvakit’s Growth Potential and Market Opportunities - TipRanks
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ... - Yahoo Finance
Blueprint Medicines Reports Strong Growth and Promising Outlook - TipRanks
Blueprint Medicines: Positive Earnings Call Highlights Growth - TipRanks
Blueprint Medicines Corp SEC 10-K Report - TradingView
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views - Benzinga
Blueprint Medicines: Q4 Earnings Snapshot - The Washington Post
Blueprint Medicines should be bought on any weakness, says Stifel - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates - MSN
Blueprint Medicines Corp earnings missed by $0.09, revenue fell short of estimates - Investing.com
Values First Advisors Inc. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines selloff to be short-lived, says Oppenheimer - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates By Investing.com - Investing.com UK
Blueprint Medicines Corp Reports Q4 Revenue of $144.1 Million, M - GuruFocus.com
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (BPMC) Blueprint Medicines Posts Q4 Net Loss $-0.79 a Share, vs. FactSet Est of $-0.67 Loss - Marketscreener.com
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - TradingView
BLUEPRINT MEDICINES Earnings Results: $BPMC Reports Quarterly Earnings - Nasdaq
Blueprint Medicines reports Q4 EPS (79c), consensus (71c) - TipRanks
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results – Company Announcement - Financial Times
Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday - Defense World
Research Analysts Offer Predictions for BPMC FY2025 Earnings - MarketBeat
Get in on Blueprint Medicines Corp’s (BPMC) buy-in window today! - SETE News
Leerink Partnrs Issues Pessimistic Outlook for BPMC Earnings - Defense World
Jennison Associates LLC Invests $31.42 Million in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Balance Sheet Dive: Blueprint Medicines Corp (BPMC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? - Nasdaq
How to interpret Blueprint Medicines Corp (BPMC)’s stock chart patterns - US Post News
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 - Financial Times
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by KBC Group NV - Defense World
Blueprint Medicines Q4 Earnings: Critical Financial Results Coming February 13 - StockTitan
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Significant Increase in Short Interest - MarketBeat
Taking on analysts’ expectations and winning: Blueprint Medicines Corp (BPMC) - SETE News
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Blueprint Medicines Corp Azioni (BPMC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rossi Christina | CHIEF OPERATING OFFICER |
Jan 21 '25 |
Sale |
110.14 |
2,274 |
250,455 |
67,109 |
| Albers Jeffrey W. | Director |
Jan 21 '25 |
Option Exercise |
36.05 |
10,000 |
360,500 |
167,557 |
| Albers Jeffrey W. | Director |
Jan 21 '25 |
Sale |
109.53 |
15,161 |
1,660,511 |
152,396 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):